NO317699B1 - Fremgangsmate for fremstilling av et proteinkonsentrat som er koagulerbar med trombin, og som inneholder for det meste fibrinogen, endogen faktor XIII og fibronektin. - Google Patents

Fremgangsmate for fremstilling av et proteinkonsentrat som er koagulerbar med trombin, og som inneholder for det meste fibrinogen, endogen faktor XIII og fibronektin. Download PDF

Info

Publication number: NO317699B1
Authority: NO; Norway
Prior art keywords: proteins; concentrate; solution; protein; thrombin
Prior art date: 1993-02-23

Application number

NO19963602A

Other languages

English (en)

Norwegian (no)

Other versions

NO963602L (no

NO963602D0 (no

Inventor

Trung Bui-Khac

Lise Lavoie

Picq Dominique Michel St

Original Assignee

Haemacure Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-23

Filing date

1996-08-28

Publication date

2004-12-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25683079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO317699(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-28 Application filed by Haemacure Corp filed Critical Haemacure Corp

1996-08-28 Publication of NO963602D0 publication Critical patent/NO963602D0/no

1996-10-17 Publication of NO963602L publication Critical patent/NO963602L/no

2004-12-06 Publication of NO317699B1 publication Critical patent/NO317699B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 45
102000004169 proteins and genes Human genes 0.000 title claims abstract description 45
239000012141 concentrate Substances 0.000 title claims abstract description 33
108010049003 Fibrinogen Proteins 0.000 title claims abstract description 19
102000008946 Fibrinogen Human genes 0.000 title claims abstract description 19
229940012952 fibrinogen Drugs 0.000 title claims abstract description 19
108010071289 Factor XIII Proteins 0.000 title claims abstract description 18
229940012444 factor xiii Drugs 0.000 title claims abstract description 14
108090000190 Thrombin Proteins 0.000 title claims abstract description 13
229960004072 thrombin Drugs 0.000 title claims abstract description 13
108010067306 Fibronectins Proteins 0.000 title claims abstract description 8
102000016359 Fibronectins Human genes 0.000 title claims abstract description 8
238000004519 manufacturing process Methods 0.000 title description 12
238000000034 method Methods 0.000 claims abstract description 37
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims abstract description 11
230000008569 process Effects 0.000 claims abstract description 11
241001465754 Metazoa Species 0.000 claims abstract description 7
238000005185 salting out Methods 0.000 claims abstract description 5
239000000243 solution Substances 0.000 claims description 25
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 20
239000002244 precipitate Substances 0.000 claims description 19
229960002885 histidine Drugs 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 10
238000001556 precipitation Methods 0.000 claims description 9
239000007983 Tris buffer Substances 0.000 claims description 8
238000005063 solubilization Methods 0.000 claims description 8
230000007928 solubilization Effects 0.000 claims description 8
238000003756 stirring Methods 0.000 claims description 8
102000004506 Blood Proteins Human genes 0.000 claims description 5
108010017384 Blood Proteins Proteins 0.000 claims description 5
239000003599 detergent Substances 0.000 claims description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
229920000053 polysorbate 80 Polymers 0.000 claims description 5
230000002378 acidificating effect Effects 0.000 claims description 4
238000004108 freeze drying Methods 0.000 claims description 4
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
239000001509 sodium citrate Substances 0.000 claims description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
230000009849 deactivation Effects 0.000 claims description 3
238000011026 diafiltration Methods 0.000 claims description 3
238000000502 dialysis Methods 0.000 claims description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
238000005406 washing Methods 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
235000011056 potassium acetate Nutrition 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
238000004062 sedimentation Methods 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000001632 sodium acetate Substances 0.000 claims description 2
235000017281 sodium acetate Nutrition 0.000 claims description 2
238000011146 sterile filtration Methods 0.000 claims description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
230000003381 solubilizing effect Effects 0.000 claims 1
230000001070 adhesive effect Effects 0.000 abstract description 23
239000000853 adhesive Substances 0.000 abstract description 18
238000005345 coagulation Methods 0.000 abstract description 7
230000015271 coagulation Effects 0.000 abstract description 7
102000013566 Plasminogen Human genes 0.000 abstract description 5
108010051456 Plasminogen Proteins 0.000 abstract description 5
230000008901 benefit Effects 0.000 abstract description 4
239000003364 biologic glue Substances 0.000 abstract description 4
238000002156 mixing Methods 0.000 abstract description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 abstract description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
230000036760 body temperature Effects 0.000 abstract 1
229910052791 calcium Inorganic materials 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
238000000975 co-precipitation Methods 0.000 abstract 1
238000000926 separation method Methods 0.000 abstract 1
239000000047 product Substances 0.000 description 20
108010073385 Fibrin Proteins 0.000 description 8
102000009123 Fibrin Human genes 0.000 description 8
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
229950003499 fibrin Drugs 0.000 description 8
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
241000700605 Viruses Species 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
108010088751 Albumins Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000002779 inactivation Effects 0.000 description 4
239000012460 protein solution Substances 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
230000020764 fibrinolysis Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
238000004026 adhesive bonding Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
238000012742 biochemical analysis Methods 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
230000001112 coagulating effect Effects 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
239000012467 final product Substances 0.000 description 2
230000035876 healing Effects 0.000 description 2
230000002439 hemostatic effect Effects 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000009776 industrial production Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
DTGFBBFYTMOQGC-ZMPKAQECSA-N (1e)-2-[6-[[amino-[(e)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic aci Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O.C=1C=C(Cl)C=CC=1NC(/N)=N/C(N)=NCCCCCCN=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1 DTGFBBFYTMOQGC-ZMPKAQECSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920001651 Cyanoacrylate Polymers 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
101800000974 Fibrinopeptide A Proteins 0.000 description 1
101800003778 Fibrinopeptide B Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
229940122791 Plasmin inhibitor Drugs 0.000 description 1
108010077971 Plasminogen Inactivators Proteins 0.000 description 1
102000010752 Plasminogen Inactivators Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
239000004826 Synthetic adhesive Substances 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229940050528 albumin Drugs 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
238000013130 cardiovascular surgery Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
-1 citrate Chemical class 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002682 general surgery Methods 0.000 description 1
238000000892 gravimetry Methods 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001965 increasing effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000010907 mechanical stirring Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
239000002806 plasmin inhibitor Substances 0.000 description 1
239000002797 plasminogen activator inhibitor Substances 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000001626 skin fibroblast Anatomy 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000003106 tissue adhesive Substances 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Surgery (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Materials For Medical Uses (AREA)
Adhesives Or Adhesive Processes (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO19963602A 1993-02-23 1996-08-28 Fremgangsmate for fremstilling av et proteinkonsentrat som er koagulerbar med trombin, og som inneholder for det meste fibrinogen, endogen faktor XIII og fibronektin. NO317699B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/021,302 US5395923A (en)	1993-02-23	1993-02-23	Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
PCT/CA1994/000105 WO1995023167A1 (en)	1993-02-23	1994-02-28	Process for the obtention of a biological adhesive comprising fibrinogen, factor xiii and fibronectin

Publications (3)

Publication Number	Publication Date
NO963602D0 NO963602D0 (no)	1996-08-28
NO963602L NO963602L (no)	1996-10-17
NO317699B1 true NO317699B1 (no)	2004-12-06

Family

ID=25683079

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19963602A NO317699B1 (no)	1993-02-23	1996-08-28	Fremgangsmate for fremstilling av et proteinkonsentrat som er koagulerbar med trombin, og som inneholder for det meste fibrinogen, endogen faktor XIII og fibronektin.

Country Status (12)

Country	Link
US (1)	US5395923A (de)
EP (1)	EP0748337B1 (de)
JP (1)	JP3492694B2 (de)
AT (1)	ATE181738T1 (de)
AU (1)	AU678439B2 (de)
CA (1)	CA2113660C (de)
DE (1)	DE69419324T2 (de)
DK (1)	DK0748337T3 (de)
ES (1)	ES2135564T3 (de)
NO (1)	NO317699B1 (de)
RU (1)	RU2130946C1 (de)
WO (1)	WO1995023167A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6197325B1 (en)	1990-11-27	2001-03-06	The American National Red Cross	Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) *	1990-11-27	2000-09-12	The American National Red Cross	Supplemented and unsupplemented tissue sealants, method of their production and use
US6054122A (en)	1990-11-27	2000-04-25	The American National Red Cross	Supplemented and unsupplemented tissue sealants, methods of their production and use
US5792835A (en) *	1991-09-05	1998-08-11	Baxter International Inc.	Method of preparing a topical fibrinogen complex
SE9301582D0 (sv) *	1993-05-07	1993-05-07	Kabi Pharmacia Ab	Purification of plasma proteins
US5585007A (en)	1994-12-07	1996-12-17	Plasmaseal Corporation	Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant
US6074663A (en) *	1995-01-16	2000-06-13	Baxter International Inc.	Method of using cross-linked fibrin material
JPH08333277A (ja) *	1995-06-05	1996-12-17	Hoechst Japan Ltd	ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
AR013829A1 (es)	1996-07-12	2001-01-31	Baxter Int	Un dispositivo medico para suministrar cantidades volumetricas de un primer y un segundo fluido, bioquimicamente reactivos, y metodo para suministrarfibrina a una superficie con dicho dispositivo
WO1998012274A1 (en) *	1996-09-23	1998-03-26	Chandrashekar Pathak	Methods and devices for preparing protein concentrates
US8003705B2 (en) *	1996-09-23	2011-08-23	Incept Llc	Biocompatible hydrogels made with small molecule precursors
US6132598A (en) *	1997-01-08	2000-10-17	Bristol-Myers Squibb Company	Centrifuge apparatus with temperature control means
IL130728A (en) *	1997-01-08	2002-11-10	Bristol Myers Squibb Co	Centrifuge apparatus with temperature control means
ZA983497B (en)	1997-04-28	1999-10-25	Lilly Co Eli	Activated protein c formulations.
US6630137B1 (en)	1997-04-28	2003-10-07	Eli Lilly And Company	Activated protein C formulations
US5900270A (en) *	1997-09-22	1999-05-04	Cobe Laboratories, Inc.	Technique for testing and coating a microporous membrane
US5981254A (en) *	1997-10-30	1999-11-09	Haemacure Corporation	Process for producing thrombin from plasma
ATE439150T1 (de) *	1997-11-17	2009-08-15	Haemacure Corp	Ein hyaluronsäurederivat enthaltende fibrinsiegel-oder fibrinklebmasse
BE1012536A3 (fr)	1998-11-04	2000-12-05	Baxter Int	Element muni d'une couche de fibrine sa preparation et son utilisation.
EP1137373A4 (de) *	1998-12-04	2004-05-19	Chandrashekhar P Pathak	Biokompatible, vernetzte polymere
US6310036B1 (en)	1999-01-09	2001-10-30	Last Chance Tissue Adhesives Corporation	High strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces
EP1151007B1 (de) *	1999-02-12	2006-05-03	Baxter Aktiengesellschaft	Verfahren zur herstellung von fibrinogen und fibronectin sowie proteinzusammesetzungen, welche damit herstellbar sind
JP4771594B2 (ja) *	1999-02-12	2011-09-14	バクスターアクチェンゲゼルシャフト	フィブリノーゲンおよびフィブロネクチンをベースとする製剤を生成するための方法ならびにこの方法により入手可能なタンパク質組成物
US7654998B1 (en)	1999-08-23	2010-02-02	Aeris Therapeutics, Inc.	Tissue volume reduction
US6610043B1 (en)	1999-08-23	2003-08-26	Bistech, Inc.	Tissue volume reduction
US6960463B2 (en)	1999-12-23	2005-11-01	Csl Limited	Separation of fibrinogen from plasma proteases
US7204981B2 (en) *	2000-03-28	2007-04-17	Eli Lilly And Company	Methods of treating diseases with activated protein C
US7087578B2 (en)	2000-05-24	2006-08-08	Eli Lilly And Company	Formulations and methods for treating hypercoagulable states
US6648911B1 (en)	2000-11-20	2003-11-18	Avantec Vascular Corporation	Method and device for the treatment of vulnerable tissue site
US20030229333A1 (en) *	2002-02-22	2003-12-11	Control Delivery Systems, Inc.	Methods for treating otic disorders
CA2475738A1 (en) *	2002-03-08	2003-09-18	Eli Lilly And Company	Activated protein c formulations
US20030205538A1 (en) *	2002-05-03	2003-11-06	Randel Dorian	Methods and apparatus for isolating platelets from blood
US7992725B2 (en)	2002-05-03	2011-08-09	Biomet Biologics, Llc	Buoy suspension fractionation system
US7374678B2 (en) *	2002-05-24	2008-05-20	Biomet Biologics, Inc.	Apparatus and method for separating and concentrating fluids containing multiple components
US7832566B2 (en)	2002-05-24	2010-11-16	Biomet Biologics, Llc	Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
AU2003249642A1 (en)	2002-05-24	2003-12-12	Biomet Manufacturing Corp.	Apparatus and method for separating and concentrating fluids containing multiple components
US20060278588A1 (en)	2002-05-24	2006-12-14	Woodell-May Jennifer E	Apparatus and method for separating and concentrating fluids containing multiple components
US7845499B2 (en) *	2002-05-24	2010-12-07	Biomet Biologics, Llc	Apparatus and method for separating and concentrating fluids containing multiple components
GB0216001D0 (en)	2002-07-10	2002-08-21	Nat Blood Authority	Process and composition
US7135027B2 (en) *	2002-10-04	2006-11-14	Baxter International, Inc.	Devices and methods for mixing and extruding medically useful compositions
RU2224540C1 (ru) *	2002-12-15	2004-02-27	Люляева Ольга Дамировна	Биологический адгезивный клей
RU2253474C1 (ru) *	2003-10-23	2005-06-10	Айсина Роза Бакировна	Способ получения растворимого фибрин-мономера
ES2530989T3 (es) *	2004-10-20	2015-03-09	Ethicon Inc	Hemostático absorbible
US20060258995A1 (en) *	2004-10-20	2006-11-16	Pendharkar Sanyog M	Method for making a reinforced absorbable multilayered fabric for use in medical devices
US9358318B2 (en)	2004-10-20	2016-06-07	Ethicon, Inc.	Method of making a reinforced absorbable multilayered hemostatic wound dressing
US7866485B2 (en)	2005-02-07	2011-01-11	Hanuman, Llc	Apparatus and method for preparing platelet rich plasma and concentrates thereof
JP4961354B2 (ja)	2005-02-07	2012-06-27	ハヌマンリミテッドライアビリティカンパニー	多血小板血漿濃縮装置および方法
WO2006086201A2 (en) *	2005-02-07	2006-08-17	Hanuman Llc	Platelet rich plasma concentrate apparatus and method
CN1911440A (zh) *	2005-08-08	2007-02-14	上海莱士血制品有限公司	一种用于形成纤维蛋白膜的试剂盒及其应用
US8567609B2 (en)	2006-05-25	2013-10-29	Biomet Biologics, Llc	Apparatus and method for separating and concentrating fluids containing multiple components
US8430813B2 (en) *	2006-05-26	2013-04-30	Depuy Spine, Inc.	Illuminated surgical access system including a surgical access device and integrated light emitter
WO2008097581A1 (en) *	2007-02-06	2008-08-14	Incept, Llc	Polymerization with precipitation of proteins for elution in physiological solution
US20090227981A1 (en) *	2007-03-05	2009-09-10	Bennett Steven L	Low-Swelling Biocompatible Hydrogels
US20090227689A1 (en) *	2007-03-05	2009-09-10	Bennett Steven L	Low-Swelling Biocompatible Hydrogels
JP5479319B2 (ja)	2007-04-12	2014-04-23	バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー	ブイ式懸濁液分画システム
US8328024B2 (en)	2007-04-12	2012-12-11	Hanuman, Llc	Buoy suspension fractionation system
US8067028B2 (en) *	2007-08-13	2011-11-29	Confluent Surgical Inc.	Drug delivery device
WO2009108890A1 (en)	2008-02-27	2009-09-03	Biomet Biologics, Llc	Methods and compositions for delivering interleukin-1 receptor antagonist
WO2009111338A1 (en) *	2008-02-29	2009-09-11	Biomet Manufacturing Corp.	A system and process for separating a material
US8012077B2 (en) *	2008-05-23	2011-09-06	Biomet Biologics, Llc	Blood separating device
JP5890182B2 (ja)	2009-02-12	2016-03-22	インセプトエルエルシー	ヒドロゲルプラグによる薬物送達
US8187475B2 (en)	2009-03-06	2012-05-29	Biomet Biologics, Llc	Method and apparatus for producing autologous thrombin
US8313954B2 (en) *	2009-04-03	2012-11-20	Biomet Biologics, Llc	All-in-one means of separating blood components
US9011800B2 (en)	2009-07-16	2015-04-21	Biomet Biologics, Llc	Method and apparatus for separating biological materials
US8591391B2 (en)	2010-04-12	2013-11-26	Biomet Biologics, Llc	Method and apparatus for separating a material
US9642956B2 (en)	2012-08-27	2017-05-09	Biomet Biologics, Llc	Apparatus and method for separating and concentrating fluids containing multiple components
US9895418B2 (en)	2013-03-15	2018-02-20	Biomet Biologics, Llc	Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en)	2013-03-15	2014-09-18	Biomet Biologics, Llc	Treatment of collagen defects using protein solutions
US10143725B2 (en)	2013-03-15	2018-12-04	Biomet Biologics, Llc	Treatment of pain using protein solutions
US10208095B2 (en)	2013-03-15	2019-02-19	Biomet Manufacturing, Llc	Methods for making cytokine compositions from tissues using non-centrifugal methods
US9950035B2 (en)	2013-03-15	2018-04-24	Biomet Biologics, Llc	Methods and non-immunogenic compositions for treating inflammatory disorders
RU2561676C1 (ru) *	2014-04-07	2015-08-27	Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации	Способ получения клеящей массы
US9932388B2 (en)	2014-11-13	2018-04-03	Hemarus Therapeutics Limited	Chromatographic process for producing high purity fibrinogen and thrombin
US9713810B2 (en)	2015-03-30	2017-07-25	Biomet Biologics, Llc	Cell washing plunger using centrifugal force
US9757721B2 (en)	2015-05-11	2017-09-12	Biomet Biologics, Llc	Cell washing plunger using centrifugal force

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2826533A (en) *	1954-03-15	1958-03-11	Cutter Lab	Stable fibrinogen solutions and method for producing same
JPS5598196A (en) *	1979-01-16	1980-07-25	Meito Sangyo Kk	Fractionation of fibrinogen or its constituents and their use
AT359652B (de) *	1979-02-15	1980-11-25	Immuno Ag	Verfahren zur herstellung eines gewebekleb- stoffes
AT390001B (de) *	1984-09-28	1990-03-12	Immuno Ag	Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
DE3622642A1 (de) *	1986-07-05	1988-01-14	Behringwerke Ag	Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
US4876241A (en) *	1987-05-22	1989-10-24	Armour Pharmaceutical Company	Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
FR2618784B1 (fr) *	1987-07-30	1990-04-06	Lille Transfusion Sanguine	Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique
US4877608A (en) *	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
US5030215A (en) *	1990-01-03	1991-07-09	Cryolife, Inc.	Preparation of fibrinogen/factor XIII precipitate
AU1461592A (en) *	1991-02-07	1992-09-07	Fibratek, Inc.	Fibrinogen based adhesive
EP0534178B1 (de) *	1991-09-27	2001-04-18	Omrix Biopharmaceuticals S.A.	Verbesserter Gewebekleber, zubereitet aus Kryopräzipitat
US5290918A (en) *	1993-02-23	1994-03-01	Haemacure Biotech Inc.	Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation

1993
- 1993-02-23 US US08/021,302 patent/US5395923A/en not_active Expired - Lifetime
1994
- 1994-01-18 CA CA002113660A patent/CA2113660C/en not_active Expired - Fee Related
- 1994-02-28 AT AT94908221T patent/ATE181738T1/de not_active IP Right Cessation
- 1994-02-28 DE DE69419324T patent/DE69419324T2/de not_active Expired - Lifetime
- 1994-02-28 ES ES94908221T patent/ES2135564T3/es not_active Expired - Lifetime
- 1994-02-28 EP EP94908221A patent/EP0748337B1/de not_active Expired - Lifetime
- 1994-02-28 JP JP52203595A patent/JP3492694B2/ja not_active Expired - Fee Related
- 1994-02-28 WO PCT/CA1994/000105 patent/WO1995023167A1/en not_active Ceased
- 1994-02-28 RU RU96119971A patent/RU2130946C1/ru active
- 1994-02-28 DK DK94908221T patent/DK0748337T3/da active
- 1994-02-28 AU AU61515/94A patent/AU678439B2/en not_active Ceased
1996
- 1996-08-28 NO NO19963602A patent/NO317699B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0748337B1 (de)	1999-06-30
CA2113660A1 (en)	1994-08-24
DE69419324T2 (de)	2000-03-02
EP0748337A1 (de)	1996-12-18
RU2130946C1 (ru)	1999-05-27
JP3492694B2 (ja)	2004-02-03
ATE181738T1 (de)	1999-07-15
NO963602L (no)	1996-10-17
US5395923A (en)	1995-03-07
WO1995023167A1 (en)	1995-08-31
ES2135564T3 (es)	1999-11-01
CA2113660C (en)	2000-05-16
DE69419324D1 (de)	1999-08-05
AU6151594A (en)	1995-09-11
JPH09509183A (ja)	1997-09-16
DK0748337T3 (da)	2000-01-17
AU678439B2 (en)	1997-05-29
NO963602D0 (no)	1996-08-28

Legal Events

Date	Code	Title	Description
2011-09-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US5395923A (en)	1995-03-07	Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
US5290918A (en)	1994-03-01	Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
US5260420A (en)	1993-11-09	Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
EP1104323B1 (de)	2008-11-05	Gerät und verfahren zur herstellung von stabilem langzeitigem thrombin aus plasma sowie so hergestelltes thrombin
EP0654078B1 (de)	2003-11-05	Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
US5330974A (en)	1994-07-19	Therapeutic fibrinogen compositions
RU2236237C2 (ru)	2004-09-20	Способ продуцирования в высокой степени вирусобезопасных компонентов для получения фибринового клея из пула плазмы человека
Weis-Fogh	1988	Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system
US5099003A (en)	1992-03-24	Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii
CN101214391B (zh)	2010-05-19	一种高效生物胶封闭剂及其应用
DK173568B1 (da)	2001-03-19	Fremgangsmåde til fremstilling af et plasmabaseret, thrombinkoagulerbart proteinkoncentrat samt herved opnåede proteinkonce
RU96119971A (ru)	1998-11-20	Способ получения биологического клея, изготовленного из концентрированных коагулирующих факторов посредством "высаливания"
NL8000936A (nl)	1980-08-19	Weefselkleefstof.
SE453799C (sv)	1998-04-06	Vävnadsbindemedel innefattande fibrinogen och faktor XIII samt förfarande för dess framställning
JP2007131638A (ja)	2007-05-31	フィブリノーゲンおよびフィブロネクチンをベースとする製剤を生成するための方法ならびにこの方法により入手可能なタンパク質組成物
HUT67051A (en)	1995-01-30	Improved tissue glue prepared by using cryoprecipitate
US5795780A (en)	1998-08-18	Method of use of autologous thrombin blood fraction in a cell culture with keratinocytes
RU2112522C1 (ru)	1998-06-10	Состав для стабилизации плазмы крови, способ пастеризации плазмы и использование стабилизированной плазмы в терапии
FI96918C (fi)	1996-09-25	Koostumus veriplasman stabiloimiseksi pastöroinnin aikana
Burnouf-Radosevich et al.	2020	Biological and rheological properties of a virally inactivated fibrin glue (Biocol): comparison to an autologous fibrin glue
de Lille	1993	llllllllllllllllllllllIlllllwglllllllllIllllllllllllllllllllllllllllllll
CA2367105C (en)	2006-06-06	A thrombin blood fraction for use in a medical procedure
NO324935B1 (no)	2008-01-07	Fibrinforseglingsmiddel avledet fra fiskeblod samt fremgangsmate for fremstilling av det samme.